Aug 7 (Reuters) – Sino Biopharmaceutical Limited: * NMPA APPROVES BENMELSTOBART WITH CHEMOTHERAPY FOLLOWED BY ANLOTINIB FOR FIRST-LINE SQ-NSCLC Further company coverage:
(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)
BRIEF-Sidike New Materials Science & Technology Plans To Invest In BOPET Base Film Expansion Project
Sept 23 (Reuters) - Jiangsu Sidike New Materials Science & Technology Co Ltd: * SAYS…
China chipmaker CanSemi seeks to raise up to $918.5 million in Shenzhen listing
HONG KONG, Sept 23 (Reuters) - Chinese chipmaker CanSemi Technology is seeking to raise 6.16…
Corporate finance chiefs lift inflation outlook, cite rates as concern – Fed survey
By Howard Schneider WASHINGTON, Sept 23 (Reuters) - Company chief financial officers expect higher inflation…
